Pfizer receives EU approval for infant usage of Nimenrix

Pfizer has announced that its meningococcal disease vaccine Nimenrix has been approved for use in infants by the European Commission.

The regulator has approved an expanded indication for Nimenrix for active immunisation against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y in infants as young as six weeks of age.

This decision was based on the results of a phase III study demonstrating the immunogenicity and safety of Nimenrix in more than 1,000 healthy infants. An initial dose given from six weeks of age is followed by a second after two months and a booster dose at 12 months.

Nimenrix is now the first and only MenACWY conjugate vaccine approved in the EU that can be administered from six weeks of age with no upper age limit, and has the broadest age indication of any conjugate vaccine in Europe for this disease.

Luis Jodar, chief medical and scientific affairs officer for Pfizer, said: "At Pfizer, our expertise in bringing new indications and therapies to people in need helps enable us to continually improve and expand our portfolio of potentially life-saving vaccines."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.